Testing drug sensitivity in micro tumors to guide treatment for colorectal cancer
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined with Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer
This study is testing whether a new 3D drug sensitivity test on tiny tumors can help guide better treatment decisions for people with colorectal cancer after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05424692 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a 3D drug sensitivity test on micro tumors (PTC) in guiding postoperative adjuvant treatment strategies for colorectal cancer. Patients aged 18 to 75 with colorectal cancer will be randomly assigned to either a PTC drug sensitivity test group or a control group that follows standard clinical practices. The study will compare clinical outcomes between the two groups, focusing on disease-free survival rates over three years. The goal is to provide real-world data supporting the use of this technology for personalized treatment approaches in colorectal cancer.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 to 75 with histologically or cytologically diagnosed colorectal cancer who require adjuvant therapy after surgery.
Not a fit: Patients with metastatic disease, those unable to provide tumor samples, or individuals with severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for colorectal cancer patients, improving their chances of disease-free survival.
How similar studies have performed: While the use of drug sensitivity testing in cancer treatment is gaining traction, this specific approach using micro tumors in a 3D context is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 \~ 75 years old, regardless of gender * Patients with colorectal cancer diagnosed by histopathology or cytology * Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy * Having at least one assessable tumor focus * ECoG physical condition score ≤ 2 points * Voluntarily participate and sign informed consent Exclusion Criteria: * Patients diagnosed with metastasis * Patients who cannot obtain tumor samples * Pregnant and lactating women * Patients with poor compliance * Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment * Patients with other malignant tumors * Suffering from serious mental and nervous system diseases * The researchers believe that patients should not be selected for this study
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Guole Lin
- Email: linguole@126.com
- Phone: 13801081483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.